https://www.selleckchem.com/products/unc8153.html
V114 vaccination produced a gain of 2,095 QALYs and 6,320 LYs compared with no vaccination, leading to incremental cost-effectiveness ratios of CHF 17,866/QALY and CHF 15,616/QALY gained from a health care payer and societal perspective, respectively. This evidence justifies the implementation of V114 vaccination among high-risk adults in Switzerland. This evidence justifies the implementation of V114 vaccination among high-risk adults in Switzerland. A qualitative systematic review was undertaken to identify the therapeutic impact of a
Like
Comment
Share
